FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2972175093> ?p ?o ?g. }

• W2972175093 abstract "Background Although delirium is typically an acute reversible cognitive impairment, its presence is associated with devastating impact on both short‐term and long‐term outcomes for critically ill patients. Advances in our understanding of the negative impact of delirium on patient outcomes have prompted trials evaluating multiple pharmacological interventions. However, considerable uncertainty surrounds the relative benefits and safety of available pharmacological interventions for this population. Objectives Primary objective 1. To assess the effects of pharmacological interventions for treatment of delirium on duration of delirium in critically ill adults with confirmed or documented high risk of delirium Secondary objectives To assess the following: 1. effects of pharmacological interventions on delirium‐free and coma‐free days; days with coma; delirium relapse; duration of mechanical ventilation; intensive care unit (ICU) and hospital length of stay; mortality; and long‐term outcomes (e.g. cognitive; discharge disposition; health‐related quality of life); and 2. the safety of such treatments for critically ill adult patients. Search methods We searched the following databases from their inception date to 21 March 2019: Ovid MEDLINE®, Ovid MEDLINE® In‐Process & Other Non‐Indexed Citations, Embase Classic+Embase, and PsycINFO using the Ovid platform. We also searched the Cochrane Library on Wiley, the International Prospective Register of Systematic Reviews (PROSPERO) (http://www.crd.york.ac.uk/PROSPERO/), the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Web of Science. We performed a grey literature search of relevant databases and websites using the resources listed in Grey Matters developed by the Canadian Agency for Drugs and Technologies in Health (CADTH). We also searched trial registries and abstracts from annual scientific critical care and delirium society meetings. Selection criteria We sought randomized controlled trials (RCTs), including quasi‐RCTs, of any pharmacological (drug) for treatment of delirium in critically ill adults. The drug intervention was to be compared to another active drug treatment, placebo, or a non‐pharmacological intervention (e.g. mobilization). We did not apply any restrictions in terms of drug class, dose, route of administration, or duration of delirium or drug exposure. We defined critically ill patients as those treated in an ICU of any specialty (e.g. burn, cardiac, medical, surgical, trauma) or high‐dependency unit. Data collection and analysis Two review authors independently identified studies from the search results; four review authors (in pairs) performed data extraction and assessed risk of bias independently. We performed data synthesis through pairwise meta‐analysis and network meta‐analysis (NMA). Our hypothetical network structure was designed to be analysed at the drug class level and illustrated a network diagram of 'nodes' (i.e. drug classes) and 'edges' (i.e. comparisons between different drug classes from existing trials), thus describing a treatment network of all possible comparisons between drug classes. We assessed the quality of the body of evidence according to GRADE, as very low, low, moderate, or high. Main results We screened 7674 citations, from which 14 trials with 1844 participants met our inclusion criteria. Ten RCTs were placebo‐controlled, and four reported comparisons of different drugs. Drugs examined in these trials were the following: antipsychotics (n = 10), alpha2 agonists (n = 3; all dexmedetomidine), statins (n = 2), opioids (n = 1; morphine), serotonin antagonists (n = 1; ondansetron), and cholinesterase (CHE) inhibitors (n = 1; rivastigmine). Only one of these trials consistently used non‐pharmacological interventions that are known to improve patient outcomes in both intervention and control groups. Eleven studies (n = 1153 participants) contributed to analysis of the primary outcome. Results of the NMA showed that the intervention with the smallest ratio of means (RoM) (i.e. most preferred) compared with placebo was the alpha2 agonist dexmedetomidine (0.58; 95% credible interval (CrI) 0.26 to 1.27; surface under the cumulative ranking curve (SUCRA) 0.895; moderate‐quality evidence). In order of descending SUCRA values (best to worst), the next best interventions were atypical antipsychotics (RoM 0.80, 95% CrI 0.50 to 1.11; SUCRA 0.738; moderate‐quality evidence), opioids (RoM 0.88, 95% CrI 0.37 to 2.01; SUCRA 0.578; very‐low quality evidence), and typical antipsychotics (RoM 0.96, 95% CrI 0.64 to1.36; SUCRA 0.468; high‐quality evidence). The NMAs of multiple secondary outcomes revealed that only the alpha2 agonist dexmedetomidine was associated with a shorter duration of mechanical ventilation (RoM 0.55, 95% CrI 0.34 to 0.89; moderate‐quality evidence), and the CHE inhibitor rivastigmine was associated with a longer ICU stay (RoM 2.19, 95% CrI 1.47 to 3.27; moderate‐quality evidence). Adverse events often were not reported in these trials or, when reported, were rare; pair‐wise analysis of QTc prolongation in seven studies did not show significant differences between antipsychotics, ondansetron, dexmedetomidine, and placebo. Authors' conclusions We identified trials of varying quality that examined six different drug classes for treatment of delirium in critically ill adults. We found evidence that the alpha2 agonist dexmedetomidine may shorten delirium duration, although this small effect (compared with placebo) was seen in pairwise analyses based on a single study and was not seen in the NMA results. Alpha2 agonists also ranked best for duration of mechanical ventilation and length of ICU stay, whereas the CHE inhibitor rivastigmine was associated with longer ICU stay. We found no evidence of a difference between placebo and any drug in terms of delirium‐free and coma‐free days, days with coma, physical restraint use, length of stay, long‐term cognitive outcomes, or mortality. No studies reported delirium relapse, resolution of symptoms, or quality of life. The ten ongoing studies and the six studies awaiting classification that we identified, once published and assessed, may alter the conclusions of the review." @default.
• W2972175093 created "2019-09-12" @default.
• W2972175093 creator A5016176164 @default.
• W2972175093 creator A5020730272 @default.
• W2972175093 creator A5023691164 @default.
• W2972175093 creator A5023921089 @default.
• W2972175093 creator A5046860959 @default.
• W2972175093 creator A5046943571 @default.
• W2972175093 creator A5059751298 @default.
• W2972175093 creator A5060373660 @default.
• W2972175093 creator A5065187538 @default.
• W2972175093 creator A5068851332 @default.
• W2972175093 date "2019-09-03" @default.
• W2972175093 modified "2023-10-01" @default.
• W2972175093 title "Pharmacological interventions for the treatment of delirium in critically ill adults" @default.
• W2972175093 cites W1494369282 @default.
• W2972175093 cites W1504124543 @default.
• W2972175093 cites W1517555081 @default.
• W2972175093 cites W153241898 @default.
• W2972175093 cites W1617328014 @default.
• W2972175093 cites W1694591858 @default.
• W2972175093 cites W186974930 @default.
• W2972175093 cites W188497340 @default.
• W2972175093 cites W1886943398 @default.
• W2972175093 cites W1916262506 @default.
• W2972175093 cites W1928798595 @default.
• W2972175093 cites W1941761351 @default.
• W2972175093 cites W1954242380 @default.
• W2972175093 cites W1963383687 @default.
• W2972175093 cites W1965050133 @default.
• W2972175093 cites W1965201247 @default.
• W2972175093 cites W1967385770 @default.
• W2972175093 cites W1971895240 @default.
• W2972175093 cites W1974028678 @default.
• W2972175093 cites W1977523138 @default.
• W2972175093 cites W1978502700 @default.
• W2972175093 cites W1983988971 @default.
• W2972175093 cites W1987609279 @default.
• W2972175093 cites W1997328542 @default.
• W2972175093 cites W2006577184 @default.
• W2972175093 cites W2008638854 @default.
• W2972175093 cites W2010565324 @default.
• W2972175093 cites W2010699829 @default.
• W2972175093 cites W2011960741 @default.
• W2972175093 cites W2030419367 @default.
• W2972175093 cites W2032833970 @default.
• W2972175093 cites W2037614372 @default.
• W2972175093 cites W2051742266 @default.
• W2972175093 cites W2055171491 @default.
• W2972175093 cites W2057765075 @default.
• W2972175093 cites W2061187046 @default.
• W2972175093 cites W2062484384 @default.
• W2972175093 cites W2074147400 @default.
• W2972175093 cites W2075090827 @default.
• W2972175093 cites W2076407172 @default.
• W2972175093 cites W2081729270 @default.
• W2972175093 cites W2082311304 @default.
• W2972175093 cites W2083720407 @default.
• W2972175093 cites W2086015715 @default.
• W2972175093 cites W2086148792 @default.
• W2972175093 cites W2087578679 @default.
• W2972175093 cites W2089942661 @default.
• W2972175093 cites W2090433825 @default.
• W2972175093 cites W2093536899 @default.
• W2972175093 cites W2093798026 @default.
• W2972175093 cites W2096883889 @default.
• W2972175093 cites W2105878139 @default.
• W2972175093 cites W2107328434 @default.
• W2972175093 cites W2109005423 @default.
• W2972175093 cites W2115415903 @default.
• W2972175093 cites W2117839048 @default.
• W2972175093 cites W2119528834 @default.
• W2972175093 cites W2122196056 @default.
• W2972175093 cites W2125435699 @default.
• W2972175093 cites W2125528441 @default.
• W2972175093 cites W2129546413 @default.
• W2972175093 cites W2130271602 @default.
• W2972175093 cites W2130851983 @default.
• W2972175093 cites W2135672238 @default.
• W2972175093 cites W2138141660 @default.
• W2972175093 cites W2138928595 @default.
• W2972175093 cites W2141710162 @default.
• W2972175093 cites W2142118676 @default.
• W2972175093 cites W2143617649 @default.
• W2972175093 cites W2144855317 @default.
• W2972175093 cites W2147088995 @default.
• W2972175093 cites W2147364251 @default.
• W2972175093 cites W2149628072 @default.
• W2972175093 cites W2150841915 @default.
• W2972175093 cites W2156098321 @default.
• W2972175093 cites W2156631753 @default.
• W2972175093 cites W2157471359 @default.
• W2972175093 cites W2164654874 @default.
• W2972175093 cites W2166843397 @default.
• W2972175093 cites W2168558795 @default.
• W2972175093 cites W2169781691 @default.
• W2972175093 cites W2170436199 @default.
• W2972175093 cites W2170892587 @default.
• W2972175093 cites W2171933338 @default.
• W2972175093 cites W2255985960 @default.

• next